Search Results - "Booser, D.J."

Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits by Yang, C. H., Gonzalez-Angulo, A. M., Reuben, J. M., Booser, D. J., Pusztai, L., Krishnamurthy, S., Esseltine, D., Stec, J., Broglio, K. R., Islam, R., Hortobagyi, G. N., Cristofanilli, M.

“…Background: Bortezomib (VELCADE®) is a potent inhibitor of the 26S proteasome with broad antitumor activity. We performed a phase II study of bortezomib to…”
Get full text

Radiation Dose Escalation for Locoregionally Recurrent Breast Cancer by Skinner, H.D, Babiera, G, Booser, D.J, Buchholz, T.A, Green, M.C, Meric-Bernstam, F, Oh, J.L, Yu, T.K, Strom, E.A

Get full text

Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations by Cristofanilli, M., Morandi, P., Krishnamurthy, S., Reuben, J.M., Lee, B.-N., Francis, D., Booser, D.J., Green, M.C., Arun, B.K., Pusztai, L., Lopez, A., Islam, R., Valero, V., Hortobagyi, G.N.

“…Novel molecular therapies for metastatic breast cancer (MBC) are necessary to improve the dismal prognosis of this condition. Imatinib mesylate (Gleevec®)…”
Get full text

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results by Holmes, F. A., alero, V., Walters, R. S., Theriault, R. L., Booser, D. J., Gibbs, H., Fraschini, G., Buzdar, A. U., Willey, J., Frye, D., Asmar, L., Hortobagyi, G. N.

“…Purpose: We and others have demonstrated the antineoplastic efficacy of paclitaxel as a single agent in metastatic breast cancer. We performed this phase I…”
Get full text

Esophageal complications from combined chemoradiotherapy (cyclophosphamide + Adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer by Umsawasdi, T, Valdivieso, M, Barkley, Jr, H T, Booser, D J, Chiuten, D F, Murphy, W K, Dhingra, H M, Dixon, C L, Farha, P, Spitzer, G

“…Esophageal complications from combined chemoradiotherapy (CCRT) were analyzed in 55 patients with limited non-small cell lung cancer. CCRT consisted of…”
Get more information